Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival

• DOI: 10.1186/s12885-022-09748-1
• Publication Date: 2022-06-27T07:02:45Z
• Authors: Giovanni Almadori; Antonella Coli; Eugenio De Corso; Dario Antonio Mele; Stefano Settimi; Giovanni Di Cintio; Francesca Brigato; Domenico Scannone; Libero Lauriola; Franco Oreste Ran...
• Keywords: Surgical oncology; Parathyroid hormone-related protein

Parathyroid hormone-related peptide (PTHrP) overexpression and poor patient outcome have been reported for many human tumors, but no studies are available in laryngeal cancer. Therefore, we studied the expression of PTHrP its receptor, parathyroid receptor type 1 (PTH1R), primary locally advanced squamous cell carcinomas (LALSCC) also relation to clinical patients.We conducted a retrospective exploratory study, using immunohistochemistry, on PTHrP, PTH1R HER1 expressions LALSCC 66 patients treated with bio-radiotherapy cetuximab.The were associated degree tumor differentiation (p = 0.01 0.04, respectively). Poorly differentiated worse prognosis, expressed at nuclear level negative. cytoplasmic normal larynx epithelium more cancer cells, suggesting an autocrine/paracrine role well tumors good prognosis. Eighty-one percent positive < 0.0001), mainly level, consistent known up-regulation gene by signaling. In multivariable analyses, had higher relative risk relapse (HR 5.49; CI 95% 1.62-22.24; p 0.006) survival 8.21; 1.19-105.00; 0.031) while those showed lower 0.18; 0.04-0.62; 0.002) 0.04-0.91; 0.029).In absence could be useful predicting response and/or resistance cetuximab combined therapies, contributing aggressive behavior cells downstream HER1.